Apixaban to Prevent Recurrence After Cryptogenic Stroke-Reply

JAMA. 2024 Jun 11;331(22):1966-1967. doi: 10.1001/jama.2024.6855.

Authors

Hooman Kamel¹, David L Tirschwell², Mitchell S V Elkind³; ARCADIA Investigators

Affiliations

¹ Department of Neurology, Weill Cornell Medicine, New York, New York.
² Department of Neurology, University of Washington, Seattle.
³ Department of Neurology, Columbia University Vagelos College of Physicians and Surgeons, New York, New York.

PMID: 38739409
DOI: 10.1001/jama.2024.6855

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Aged
Atrial Fibrillation* / complications
Atrial Fibrillation* / drug therapy
Biomarkers / analysis
Black or African American
Electrocardiography
Factor Xa Inhibitors* / therapeutic use
Female
Humans
Ischemic Stroke* / etiology
Ischemic Stroke* / prevention & control
Male
Middle Aged
Natriuretic Peptide, Brain / analysis
Pyrazoles* / therapeutic use
Pyridones* / therapeutic use
Recurrence
Secondary Prevention*
Sex Factors
Stroke / prevention & control

Substances

apixaban
Factor Xa Inhibitors
Pyrazoles
Pyridones
pro-brain natriuretic peptide (1-76)
Biomarkers
Natriuretic Peptide, Brain